secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMICUS THERAPEUTICS, INC. (—)
CIK:        0001178879
Form:       8-K
Filed at:   2023-06-13T23:59:59+00:00
Accession:  0001104659-23-070827
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amicus Therapeutics Stockholders Approve Charter Amendment and Equity Plans at Annual Meeting
--------------------------------------------------------------------------------

- Elected Lynn D. Bleil and Bradley L. Campbell as Class I directors with 230.95M and 234.19M votes for, respectively.
- Approved Amended and Restated 2007 Equity Incentive Plan with 233.61M votes for, 4.25M against.
- Ratified Ernst & Young as independent auditor for fiscal year 2023 with 244.70M votes for.
- Advisory approval of executive compensation and one-year frequency for say-on-pay votes received majority support.
- Approved 2023 Employee Stock Purchase Plan (236.77M for) and amendment to limit officer liability (182.90M for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178879/000110465923070827/0001104659-23-070827-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178879/000110465923070827/tm2318498d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-070827

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer